The agency, called the California Institute for Regenerative Medicine, has been controversial from the beginning. The question is whether Trounson can finally lend some stability to the agency’s mission of supporting stem-cell science and research to find new cures to disease — one of the most ambitious efforts worldwide in this area. See story at VentureBeat LifeSciences by David Hamilton.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more